Search Results - "Kurk, Sophie"

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy by Dijksterhuis, Willemieke P.M., Pruijt, Maarten J., Woude, Stephanie O., Klaassen, Remy, Kurk, Sophie A., Oijen, Martijn G.H., Laarhoven, Hanneke W.M.

“…Background Palliative systemic treatment in patients with advanced or metastatic esophagogastric cancer may result in improved overall survival and quality of…”
Get full text

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients by Kurk, Sophie A., Peeters, Petra H.M., Dorresteijn, Bram, Jong, Pim A., Jourdan, Marion, Kuijf, Hugo J., Punt, Cornelis J.A., Koopman, Miriam, May, Anne M.

“…Background Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy‐related toxicity, poor quality of life, and…”
Get full text

Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients by Kurk, Sophie A, Stellato, Rebecca K, Peeters, Petra HM, Dorresteijn, Bram, Jourdan, Marion, Oskam, Marieke J, Punt, Cornelis JA, Koopman, Miriam, May, Anne M

“…Knowledge of the evolution of BMI and skeletal muscle index (SMI) measurements during advanced cancer and their relationships with disease progression (PD) is…”
Get full text

Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients by Kurk, Sophie, Peeters, Petra, Stellato, Rebecca, Dorresteijn, B., Jong, Pim, Jourdan, Marion, Creemers, Geert‐Jan, Erdkamp, Frans, Jongh, Felix, Kint, Peter, Simkens, Lieke, Tanis, Bea, Tjin‐A‐Ton, Manuel, Van Der Velden, Ankie, Punt, Cornelis, Koopman, Miriam, May, Anne

“…Background Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic…”
Get full text

The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer by Derksen, Jeroen W.G., Kurk, Sophie A., Peeters, Petra H.M., Dorresteijn, Bram, Jourdan, Marion, Velden, Ankie M.T., Nieboer, Peter, Jong, Robert S., Honkoop, Aafke H., Punt, Cornelis J.A., Koopman, Miriam, May, Anne M.

“…Background Skeletal muscle mass (SMM) loss is common in metastatic colorectal cancer (mCRC) patients and associated with poor clinical outcomes, including…”
Get full text

Use of automated assessment for determining associations of low muscle mass and muscle loss with overall survival in patients with colorectal cancer – A validation study by Smit, Karel C., Derksen, Jeroen W.G., Kurk, Sophie A., Moeskops, Pim, Koopman, Miriam, Veldhuis, Wouter B., May, Anne M.

“…Low muscle mass and skeletal muscle mass (SMM) loss are associated with adverse patient outcomes, but the time-consuming nature of manual SMM quantification…”
Get full text

Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients by van der Kruijssen, Dave E W, van Rooijen, Karlijn L, Kurk, Sophie A, de Wilt, Johannes H W, Punt, Cornelis J A, Vink, Geraldine R, Elias, Sjoerd G, Koopman, Miriam

“…Uncertainty exists about a possible survival benefit of primary tumor resection (PTR) in synchronous metastatic colon cancer (mCC). Since sidedness of the…”
Get more information

A Systematic Review of the Diagnostic Value of CT Imaging in Diagnosing Otosclerosis by Wegner, Inge, van Waes, Anne M A, Bittermann, Arnold J, Buitinck, Sophie H, Dekker, Caroline F, Kurk, Sophie A, Rados, Matea, Grolman, Wilko

“…OBJECTIVE:To evaluate the diagnostic value of computed tomography (CT) in detecting otosclerosis in patients with conductive hearing loss and a clinical…”
Get full text

Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial by Kurk, Sophie A., Peeters, Petra H. M., Dorresteijn, Bram, Jong, Pim A., Jourdan, Marion, Creemers, Geert‐Jan M., Erdkamp, Frans L. G., Jongh, Felix E., Kint, Peter A. M., Poppema, Boelo J., Radema, Sandra A., Simkens, Lieke H. J., Tanis, Bea C., Tjin‐A‐Ton, Manuel L. R., Van Der Velden, Ankie, Punt, Cornelis J. A., Koopman, Miriam, May, Anne M.

“…Background Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI…”
Get full text

Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer by Derksen, Jeroen W G, Kurk, Sophie A, Oskam, Marieke J, Peeters, Petra H M, Punt, Cornelis J A, Koopman, Miriam, May, Anne M

“…Increasing evidence indicates that loss of muscle mass is associated with adverse outcomes in metastatic colorectal cancer. Here, we investigate which…”
Get full text

Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics by Molenaar‐Kuijsten, Laura, Jacobs, Bart Albertus Wilhelmus, Kurk, Sophie Alberdine, May, Anne Maria, Dorlo, Thomas Petrus Catharina, Beijnen, Jacob Hendrik, Steeghs, Neeltje, Huitema, Alwin Dagmar Redmar

“…Background A low skeletal muscle mass (SMM) has been associated with increased toxicity and shorter survival in cancer patients treated with capecitabine, an…”
Get full text

Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging (19F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer by Kurk, Sophie A., Steensma, Bart R., May, Anne M., Koopman, Miriam, Hoogduin, Hans M., van der Velden, Tijl A., Klomp, Dennis W. J., van der Kemp, Wybe J. M.

“…Trifluridine/tipiracil (TAS-102) has shown a significant overall survival benefit in patients with heavily pre-treated metastatic colorectal cancer. However,…”
Get full text

Subgroup analyses of the phase 3 CAIRO3 trial: Association of number and total volume of metastases on survival in patients with metastatic colorectal cancer based on a deep-learning automatic segmentation model by Zwart, Koen, Zeeuw, Michiel J., Stehouwer, Bertine L., Al-Toma, Dania, Kurk, Sophie, Braat, Manon N.G.J.A., de Jong, Pim A., Lagendijk, Jan J.W., May, Anne M., Koopman, Miriam, Punt, Cornelis J. A., Kazemier, Geert, Bol, Guus

“…130 Background: Maintenance treatment with capecitabine and bevacizumab after capecitabine, oxaliplatin, and bevacizumab therapy in metastatic colorectal…”
Get full text

Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial by van der Kruijssen, Dave E W, Elias, Sjoerd G, Vink, Geraldine R, van Rooijen, Karlijn L, 't Lam-Boer, Jorine, Mol, Linda, Punt, Cornelis J A, de Wilt, Johannes H W, Koopman, Miriam

“…The role of primary tumor resection (PTR) in synchronous patients with metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent…”
Get more information

Abstract 1827: The prospective Dutch colorectal cancer cohort: A prospective nation-wide observational cohort study by Coebergh van den Braak, Robert R.J., Vink, Geraldine R., van Oijen, Martijn G.H., de Noo, Mirre E., Kurk, Sophie A., Burbach, Maarten J.P., Couwenberg, Alice M., May, Anne M., Verkooijen, Helena M., Meijer, Gerrit A., Koopman, Miriam

“…Abstract The increasingly complex subclassification of tumors based on clinical and molecular characteristics, as well as the large sample sizes needed for…”
Get full text

Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients by Kurk, Sophie, Peeters, Petra H.M., Stellato, Rebecca K., Dorresteijn, Bram, Jourdan, Marion, Creemers, Geert-Jan, Erdkamp, Frans, de Jongh, Felix E., Kint, Petrus Alouisius Maria, Poppema, Boelo Jan, Radema, Sandra Anita, Simkens, Lieke H, Tanis, Bea, Tjin-A-Ton, Manuel Lucien Roy, Van Der Velden, Ankie, Punt, Cornelis J. A., Koopman, Miriam, May, Anne Maria

“…Abstract only 10087 Background: Evidence for a strong link between skeletal muscle depletion and poor outcomes in mCRC is growing. However, the impact of SMI…”
Get full text